Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Telix Pharmaceuticals Limited - American Depositary Shares
(NQ:
TLX
)
9.140
-0.280 (-2.97%)
Streaming Delayed Price
Updated: 1:10 PM EDT, Jun 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Telix Pharmaceuticals Limited - American Depositary Shares
< Previous
1
2
3
4
5
6
7
Next >
Telix and United Imaging Announce Strategic Theranostics Collaboration
Today 7:00 EDT
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
June 01, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
May 27, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
May 18, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
May 15, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
May 04, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
TLX101-Px (Pixlumi®) MAA Accepted in Europe
April 30, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
April 29, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
April 27, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
April 21, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
April 14, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)
April 13, 2026
As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche...
Via
Finterra
Topics
Economy
Initial Public Offering
Telix and Regeneron Announce Strategic Radiopharma Collaboration
April 13, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Regeneron and Telix Announce Strategic Radiopharma Collaboration
April 13, 2026
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
FDA Accepts NDA for TLX101-Px (Pixclara®)
April 09, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Strengthens Board with Additional Director Appointments
April 08, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
April 06, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Appoints David Gill as Non-Executive Director
April 01, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
March 15, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
March 09, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Investor Education Webinar
March 01, 2026
The Future of Prostate Imaging: What do physicians want?
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
February 27, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth
↗
February 26, 2026
Telix Pharmaceuticals focuses on radiopharmaceuticals for the diagnosis and treatment of cancer.
Via
The Motley Fool
Topics
Artificial Intelligence
Telix to Participate in Oppenheimer and TD Cowen Conferences
February 20, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
February 19, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
February 17, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Full Year Results 2025 Investor Webcast Notification
February 03, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
January 20, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
January 16, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
TELIX FINAL CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights
January 09, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
